arrow
A

Aaron Balog

Bristol-Myers Squibb
H指数:28
被引数:3,238

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Development of a Stereoselective and Scalable Synthesis for the Potent Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor, BMT-297376; N-((R)-1-((cis)-4-(3-(Difluoromethyl)-2-methoxypyridin-4-yl)cyclohexyl)propyl)-6-methoxynicotinamide
2021-06-292
PREAI
Conformational-Analysis-Guided Discovery of 2,3-Disubstituted Pyridine IDO1 Inhibitors

构象分析指导的2,3-二取代吡啶IDO1抑制剂的发现

2021-06-162
OAAI
Discovery of Imidazopyridines as Potent Inhibitors of Indoleamine 2,3-Dioxygenase 1 for Cancer Immunotherapy

咪唑并吡啶作为吲哚胺2,3-双加氧酶1的有效抑制剂用于癌症免疫治疗的发现

2021-03-0210
OA
Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1

BMS-986242的发现和临床前评估,一种有效的,选择性的Indoleamine-2,3-双加氧酶1抑制剂

2021-01-2820
OA
Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form

免疫调节酶吲哚胺2,3-双加氧酶通过靶向其apo形式被有效抑制

2018-03-12162
OAAI
Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate Cancer

用于治疗前列腺癌的选择性CYP17A1裂解酶抑制剂BMS-351的发现

2015-12-147
OAAI
Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer
2015-06-2621
OAAI
Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors
2015-03-1881
OAAI
BMS-983970, an oral pan-Notch inhibitor for the treatment of cancer
2014-10-011
PRE
Androgen receptor antagonists: Lead optimization and preclinical pharmacology
2010-04-010
PRE